ATE362989T1 - Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren - Google Patents

Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren

Info

Publication number
ATE362989T1
ATE362989T1 AT99908441T AT99908441T ATE362989T1 AT E362989 T1 ATE362989 T1 AT E362989T1 AT 99908441 T AT99908441 T AT 99908441T AT 99908441 T AT99908441 T AT 99908441T AT E362989 T1 ATE362989 T1 AT E362989T1
Authority
AT
Austria
Prior art keywords
recombinant adenoviruses
viruses
production
producing recombinant
viral
Prior art date
Application number
AT99908441T
Other languages
English (en)
Inventor
Tong-Chuan He
Bert Vogelstein
Kenneth Kinzler
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE362989T1 publication Critical patent/ATE362989T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99908441T 1998-02-27 1999-02-25 Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren ATE362989T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/031,917 US5922576A (en) 1998-02-27 1998-02-27 Simplified system for generating recombinant adenoviruses

Publications (1)

Publication Number Publication Date
ATE362989T1 true ATE362989T1 (de) 2007-06-15

Family

ID=21862097

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99908441T ATE362989T1 (de) 1998-02-27 1999-02-25 Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren

Country Status (7)

Country Link
US (1) US5922576A (de)
EP (1) EP1056881B1 (de)
AT (1) ATE362989T1 (de)
AU (1) AU747847B2 (de)
CA (1) CA2322066A1 (de)
DE (1) DE69936134D1 (de)
WO (1) WO1999043843A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US6420629B1 (en) * 1996-09-09 2002-07-16 B.C. Research Inc. Process of increasing plant growth and yield and modifying cellulose production in plants
BR9713368A (pt) 1996-11-20 2001-09-18 Introgen Therapeutics Inc Processo melhorado para a produção e a purificação de vetores adenovirais
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
CA2294649C (en) 1997-06-23 2007-09-25 University Of Saskatchewan Bovine adenovirus type 3 genome
JP2002509733A (ja) * 1998-03-28 2002-04-02 ユニバーシティー オブ ユタ リサーチ ファンデーション 指向性アンチセンスライブラリー
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6328958B1 (en) 1998-08-28 2001-12-11 Duke University Deleted adenovirus vectors and methods of making and administering the same
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
JP4173663B2 (ja) * 1999-09-17 2008-10-29 テヘテ ラボラトリーズ，エセ．ア．デ セ．ウベ． 組換えアデノウイルスベクター、肝臓、腎臓、肺および肥大性の瘢痕の各種の線維症の治療におけるその利用
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
US6867022B1 (en) 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
WO2001059071A2 (en) * 2000-02-09 2001-08-16 Genvec, Inc. Methods of preparing and using a viral vector library
US6830920B2 (en) * 2000-03-08 2004-12-14 University Of Iowa Research Foundation Rapid generation of recombinant adenoviral vectors
AU6368901A (en) * 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
WO2002020814A1 (en) * 2000-09-08 2002-03-14 The General Hospital Corporation Self-rearranging dna vectors
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
JP2004513638A (ja) * 2000-11-10 2004-05-13 アストラゼネカ・アクチエボラーグ ベクター
GB0027501D0 (en) * 2000-11-10 2000-12-27 Astrazeneca Ab Vector
MXPA00011713A (es) * 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
US20020177229A1 (en) * 2001-01-19 2002-11-28 Ivo Piest Swap/counter selection: a rapid cloning method
WO2003025161A1 (en) 2001-09-18 2003-03-27 Clontech Laboratories, Inc. Site-specific recombinase based method for producing adenoviral vectors
AU2003210661A1 (en) * 2002-01-24 2003-09-02 Novartis Ag Fiber shaft modifications for efficient targeting
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
JP2005536231A (ja) * 2002-05-08 2005-12-02 イントロン，インコーポレーテッド アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
WO2004028243A2 (en) 2002-08-21 2004-04-08 Revivicor, Inc. Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
US20050272030A1 (en) * 2002-09-27 2005-12-08 Powder Ject Research Limited Nucleic acid constructs for gene expression
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2005001133A2 (en) * 2003-06-03 2005-01-06 Collateral Therapeutics, Inc. Compositions and methods for high throughput construction and functional analysis of expression libraries
WO2004108755A2 (en) * 2003-06-10 2004-12-16 University Of Saskatchewan Chimeric adenovirus capsid proteins
US20070213288A1 (en) * 2003-07-17 2007-09-13 University Of South Florida Adenoviral Vector Capable of Infecting Tumor Cells and Eliminating the Function of STAT3
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US20070003520A1 (en) * 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
US7897146B2 (en) * 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
CA2553828A1 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing
WO2005070948A1 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
AU2005238527B2 (en) * 2004-04-28 2011-01-20 The Trustees Of The University Of Pennsylvania Polyvalent viral vectors and a system for production thereof
WO2006014899A2 (en) 2004-07-26 2006-02-09 Dow Global Technologies Inc. Process for improved protein expression by strain engineering
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
WO2006073496A2 (en) * 2004-07-30 2006-07-13 Targeted Genetics Corporation Recombinant aav based vaccine methods
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
CA2583306A1 (en) * 2004-10-08 2006-08-10 Intronn, Inc. Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production
EP1815029A4 (de) 2004-11-03 2009-06-10 Introgen Therapeutics Inc Neues verfahren zur herstellung und reinigung von adenovirusvektoren
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
EP1899470A4 (de) * 2005-05-23 2009-07-29 Vaxin Inc System zur schnellen herstellung replikationskompetenter adenovirus-freier rekombinanter adenovirusvektoren mit hohem titer
EP3138403A1 (de) 2005-08-09 2017-03-08 Revivicor, Inc. Ctla4-ig exprimierende transgene huftiere und verwendungen davon
KR100723009B1 (ko) * 2005-11-30 2007-05-29 한국원자력연구원 인간 ｐ３１ 유전자를 함유하는 악성 종양 치료용 약학적조성물
EP1971862B1 (de) * 2006-04-11 2010-11-10 Arena Pharmaceuticals, Inc. Verfahren zur verwendung des gpr119-rezeptors zur identifizierung von verbindungen zur erhöhung der knochenmasse bei einer person
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP1900749A1 (de) 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nukleinsäuren zur Expression von Polynukleotiden in Säuger-Krebszellen
EP2097517B1 (de) 2006-10-16 2014-06-04 Genelux Corporation Rekombinantes Lister-Stamm Vaccinia Virus kodierend für einen einzelkettigen anti-VEGF Antikörper
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
KR101530395B1 (ko) 2007-04-27 2015-06-19 피페넥스 인크. 향상된 수율 및(또는) 품질로 이종 단백질을 발현하는 특정 균주를 동정하기 위해 미생물 숙주를 신속히 스크리닝하는 방법
EP2171071B1 (de) 2007-06-15 2015-08-05 Genelux Corporation Für ein natriumabhängiges transporterprotein codierende vacciniavirus-vektoren zur bildlichen darstellung und/oder behandlung von tumoren
ES2688721T3 (es) 2007-11-01 2018-11-06 Astellas Pharma Inc. Polipéptidos y ácidos nucleicos inmunosupresores
EP2108960A1 (de) * 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY
JP6415977B2 (ja) 2011-04-15 2018-10-31 ジェネラックス・コーポレイションＧｅｎｅｌｕｘ Ｃｏｒｐｏｒａｔｉｏｎ 弱毒化ワクシニアウイルスのクローン株およびその使用方法
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN113088530A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
CN111549065B (zh) * 2020-04-01 2023-11-24 广州医科大学附属第一医院（广州呼吸中心） 应用腺病毒转导制备能够表达人源apn转基因非人动物的方法，及所得动物的应用
TW202413634A (zh) 2022-07-08 2024-04-01 美商維羅米梭公司 溶瘤痘瘡病毒及重組病毒及其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
WO1998032860A1 (en) * 1997-01-28 1998-07-30 Baxter International Inc. Methods for highly efficient generation of adenoviral vectors

Also Published As

Publication number Publication date
EP1056881B1 (de) 2007-05-23
WO1999043843A1 (en) 1999-09-02
EP1056881A1 (de) 2000-12-06
CA2322066A1 (en) 1999-09-02
DE69936134D1 (de) 2007-07-05
AU747847B2 (en) 2002-05-23
AU2787599A (en) 1999-09-15
US5922576A (en) 1999-07-13

Similar Documents

Publication Publication Date Title
ATE362989T1 (de) Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren
McGrory et al. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5
CA2321964A1 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus
NZ316389A (en) Retroviral packaging plasmid and methods of use thereof
SG55158A1 (en) Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
EP1394259A3 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
FI964536A7 (fi) DNA-rakenne homologisen rekombinaation suorittamiseksi ja sen käyttöjä
FI971783A7 (fi) Adenoviruksia, joissa ei ole elinkykyisiä kontaminoivia partikkeleita, niiden valmistus ja käyttöjä
ATE278024T1 (de) Methode zur herstellung von rekombinanten zellen
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
DE69534902D1 (de) Rekombinanter viraler DNS Vektor zur Transfektion tierischer Zellen
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
TW200516144A (en) Novel bone mineralization proteins, DNA, vectors, expression systems
HU219369B (en) Process for producing of modified chordopoxvirus by direct molecular cloning, modified chordopoxvirus and process for its use
BR9908499A (pt) Linhagens celulares embrionárias ousemelhantes a tronco produzidas portransplante nuclear de espécies cruzado
CN108795986A (zh) 一种a型血友病慢病毒载体、慢病毒及其制备方法和应用
TR200001046T2 (tr) Homolog rekombinasyonda pozitif-negatif seçimi.
DK0843731T3 (da) Adenovirusvektorer til genterapi
RU2000122617A (ru) Самореплицирующийся рекомбинантный вектор, способ его получения, вакцина для иммунизации против вич с помощью днк, содержащая указанный вектор, способ лечения или профилактики вич и клетка-хозяин, содержащая указанный вектор
DK0880594T3 (da) Retroviral vektor og dens anvendelse i genterapi
MX2024009778A (es) Producción de virus de la estomatitis vesicular recombinante de alto título en cultivo celular en suspensión
WO2025011146A1 (zh) 一种复制缺陷型重组病毒扩增用细胞系的制备方法和缺陷性病毒及其应用
CN117701525A (zh) 一种制备线性共价闭合dna微载体的酶切体系及其应用
TWI316958B (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties